X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Biocon Ltd with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs ACTAVIS (US) - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 BIOCON    ACTAVIS
EQUITY SHARE DATA
    BIOCON
Mar-18
ACTAVIS
Dec-14
BIOCON /
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,18818,654-   
Low Rs30511,378-   
Sales per share (Unadj.) Rs68.73,359.1-  
Earnings per share (Unadj.) Rs7.6-419.2-  
Cash flow per share (Unadj.) Rs14.0308.2-  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs86.37,285.7-  
Shares outstanding (eoy) m600.00265.90-   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.94.5 243.0%   
Avg P/E ratio x98.9-35.8 -275.9%  
P/CF ratio (eoy) x53.448.7 109.7%  
Price / Book Value ratio x8.62.1 419.5%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m447,9003,992,820 11.2%   
No. of employees `0006.121.6 28.5%   
Total wages/salary Rs m9,3110-   
Avg. sales/employee Rs Th6,705.841,350.9 16.2%   
Avg. wages/employee Rs Th1,514.20-   
Avg. net profit/employee Rs Th736.9-5,160.2 -14.3%   
INCOME DATA
Net Sales Rs m41,234893,180 4.6%  
Other income Rs m2,062-2,229 -92.5%   
Total revenues Rs m43,296890,950 4.9%   
Gross profit Rs m8,291114,742 7.2%  
Depreciation Rs m3,851193,406 2.0%   
Interest Rs m61528,173 2.2%   
Profit before tax Rs m5,887-109,066 -5.4%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-8,000 0.0%   
Tax Rs m1,569-5,607 -28.0%   
Profit after tax Rs m4,531-111,459 -4.1%  
Gross profit margin %20.112.8 156.5%  
Effective tax rate %26.75.1 518.4%   
Net profit margin %11.0-12.5 -88.1%  
BALANCE SHEET DATA
Current assets Rs m41,486470,591 8.8%   
Current liabilities Rs m21,413343,199 6.2%   
Net working cap to sales %48.714.3 341.3%  
Current ratio x1.91.4 141.3%  
Inventory Days Days6458 110.2%  
Debtors Days Days9466 142.1%  
Net fixed assets Rs m50,661109,066 46.4%   
Share capital Rs m3,0000-   
"Free" reserves Rs m48,8080-   
Net worth Rs m51,8081,937,274 2.7%   
Long term debt Rs m17,8981,015,169 1.8%   
Total assets Rs m99,8973,550,385 2.8%  
Interest coverage x10.6-2.9 -368.2%   
Debt to equity ratio x0.30.5 65.9%  
Sales to assets ratio x0.40.3 164.1%   
Return on assets %5.2-2.3 -219.6%  
Return on equity %8.7-5.8 -152.0%  
Return on capital %9.6-3.0 -320.0%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m4,7100-   
CASH FLOW
From Operations Rs m6,621153,376 4.3%  
From Investments Rs m-6,840-367,242 1.9%  
From Financial Activity Rs m-2,397206,337 -1.2%  
Net Cashflow Rs m-2,612-7,529 34.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 68.38 Rs / USD

Compare BIOCON With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare BIOCON With: WYETH LTD  SHASUN PHARMA  NATCO PHARMA  TORRENT PHARMA  ALEMBIC LTD  



Today's Market

Indian Indices Continue Momentum; Sensex Ends 268 Points Higher(Closing)

After opening the day marginally higher, Indian share markets continued their momentum and ended their day on a positive note.

Related Views On News

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)

Mar 6, 2019

Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Mar 19, 2019 (Close)

TRACK BIOCON

BIOCON - UNICHEM LAB COMPARISON

COMPARE BIOCON WITH

MARKET STATS